Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results

Citius Oncology (NASDAQ:CTOR) released its quarterly earnings results on Tuesday. The company reported ($0.06) EPS for the quarter, Zacks reports.

Citius Oncology Price Performance

Citius Oncology stock traded up $0.02 on Tuesday, reaching $1.27. The company’s stock had a trading volume of 376,645 shares, compared to its average volume of 972,712. The business’s fifty day moving average price is $1.40 and its 200 day moving average price is $1.90. The company has a market cap of $106.06 million, a price-to-earnings ratio of -4.54 and a beta of 2.98. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.02 and a current ratio of 0.35. Citius Oncology has a twelve month low of $0.55 and a twelve month high of $6.19.

Institutional Investors Weigh In On Citius Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its position in shares of Citius Oncology by 5,256.9% during the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after buying an additional 8,411 shares during the period. Citadel Advisors LLC bought a new stake in Citius Oncology in the third quarter valued at approximately $36,000. Geode Capital Management LLC increased its holdings in shares of Citius Oncology by 179.0% during the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock worth $249,000 after acquiring an additional 36,758 shares during the last quarter. Jane Street Group LLC acquired a new stake in Citius Oncology during the 2nd quarter valued at $465,000. Finally, Armistice Capital LLC bought a new position in Citius Oncology during the third quarter worth $15,582,000. Institutional investors own 70.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Citigroup raised Citius Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, September 23rd. Maxim Group raised Citius Oncology from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a research report on Tuesday, September 23rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Oncology in a report on Monday. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Citius Oncology has an average rating of “Hold” and an average price target of $6.00.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.